Skip to main content

Table 1 Baseline characteristics

From: Occurrence of anterior uveitis in patients with spondyloarthritis treated with tumor necrosis factor inhibitors: comparing the soluble receptor to monoclonal antibodies in a large observational cohort

 Monoclonal antibodiesSoluble receptor (etanercept)Total
Number of patients203/429 (47.3)226/429 (52.7)429/429
SpA (excluding PsA)146/203 (71.9)156/226 (69.0)302/429 (70.4)
PsA57/203 (28.1)70/226 (31.0)127/429 (29.6)
Men128/203 (63.1)133/226 (58.8)261/429 (60.8)
Age, years, mean (SD)42.4 (12.3)44.0 (12.9)43.2 (12.4)
HLA B27111/175 (63.4)119/182 (65.3)230/357 (64.4)
 MD28/203 (13.8)44/226 (19.5)72/429 (16.8)
Time between diagnosis and introduction of the first TNF inhibitor, years, mean (SD)6.9 (8.2)7.6 (8.7)7.3 (8.5)
 MD8/203 (3.9)12/226 (5.3)20/429 (4.7)
History of extra-articular symptoms before treatment137/197 (69.5)*119/217 (54.8)*256/414 (61.8)
 MD6/203 (3.0)9/226 (4.0)15/429 (3.5)
Uveitis41/188 (21.8)33/214 (15.4)74/402 (18.4)
 MD15/203 (7.4)12/226 (5.3)27/429 (6.3)
Psoriasis72/188 (38.3)81/210 (38.6)153/398 (38.4)
 MD15/203 (7.4)16/226 (7.1)31/429 (7.2)
IBD19/203 (9.4)*2/226 (0.9)*21/429 (4.9)
csDMARD treatment   
 Patients with sDMARD54/130 (41.5)56/151 (37.1)110/281 (39.1)
 Patients without sDMARD76/130 (58.5)95/151 (62.9)171/281 (60.9)
 MD73/203 (36.0)75/226 (33.2)148/429 (34.5)
Methotrexate44/130 (33.6)44/151 (29.1)88/281 (31.3)
Leflunomide2/130 (1.5)2/151 (1.3)4/281 (1.4)
Sulfasalazine8/130 (6.2)10/151 (6.6)18/281 (6.4)
  1. Data are n (%) unless indicated
  2. MD missing data, SD standard deviation, IBD inflammatory bowel disease, PsA psoriatic arthritis, sDMARD synthetic disease-modifying anti-rheumatic drug
  3. *p < 0.05